Drug Interaction Report

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Concomitant or consecutive use of concizumab and emicizumab may have additive effects on thrombin generation and increase the risk of thrombosis. In clinical studies, hemophilia A patients with FVIII inhibitors were required to discontinue emicizumab for at least 180 days before receiving concizumab. Clinical data about this interaction are lacking.

MANAGEMENT: When changing from another anti-tissue factor pathway inhibitor product to concizumab, the previous product's half-life should be taken into consideration. Due to the long half-life of emicizumab, some authorities recommend that it be ceased for at least 180 days prior to starting treatment with concizumab in Hemophilia A patients with FVIII inhibitors. Close monitoring for thromboembolic events is recommended in patients with known risk factors for thromboembolism (e.g., prior thrombosis, hyperlipidemia, hypertension, smoking). Patients should be advised to seek immediate medical attention if they develop symptoms of thromboembolism, such as shortness of breath, chest pain, hemoptysis, or arm or leg swelling or pain.